Lipid MetabolismMarch 18, 20264 min read

Q-Bank Breakdown: HMG-CoA reductase — Why Every Answer Choice Matters

Clinical vignette on HMG-CoA reductase. Explain correct answer, then systematically address each distractor. Tag: Biochemistry > Lipid Metabolism.

Q-Bank Breakdown: HMG-CoA Reductase — Why Every Answer Choice Matters

Tag: Biochemistry > Lipid Metabolism

HMG-CoA reductase questions are classic Step 1 and still show up clinically on Step 2—because they sit at the intersection of biochemistry, pharmacology (statins), genetics, and cardiovascular risk. The key to scoring high isn’t just knowing the right enzyme—it’s knowing why every other lipid enzyme is wrong in that specific vignette.

Clinical Vignette (Q-bank style)

A 52-year-old man with type 2 diabetes and hypertension comes to clinic for follow-up. He has a 35–pack-year smoking history. His fasting lipid panel shows:

  • Total cholesterol: 265 mg/dL
  • LDL-C: 190 mg/dL
  • HDL-C: 34 mg/dL
  • Triglycerides: 135 mg/dL

He is started on a medication that lowers LDL cholesterol by inhibiting the rate-limiting step of cholesterol synthesis in the liver. Two months later, his LDL has decreased substantially, but he reports proximal muscle aches. Labs show mild elevation in CK.

Which enzyme is directly inhibited by this medication?

A. Cholesterol ester transfer protein (CETP)
B. HMG-CoA reductase
C. HMG-CoA synthase
D. Lecithin–cholesterol acyltransferase (LCAT)
E. LDL receptor (LDLR)

Correct Answer: B. HMG-CoA reductase

Why it’s correct

The drug described is a statin (e.g., atorvastatin, rosuvastatin), which:

  • Competitively inhibits HMG-CoA reductase
  • Blocks conversion of HMG-CoA → mevalonate
  • Decreases hepatic cholesterol synthesis → upregulates LDL receptors on hepatocytes
  • Increases LDL clearance from plasma → lowers LDL the most

High-yield USMLE facts

  • HMG-CoA reductase is the rate-limiting step in cholesterol biosynthesis.
  • It is located in the cytosol and smooth ER of hepatocytes.
  • Statin adverse effects:
    • Myopathy/myalgias, ↑ CK (risk increases with drug interactions)
    • Hepatotoxicity (monitor LFTs in symptomatic patients)
    • Rare: rhabdomyolysis
  • Statins are contraindicated in pregnancy (cholesterol needed for fetal development).

Why Each Distractor Matters (and why it’s wrong here)

A. CETP (Cholesteryl ester transfer protein)

What it does:
Transfers cholesteryl esters from HDL → VLDL/LDL in exchange for triglycerides (part of reverse cholesterol transport remodeling).

Why it’s wrong in this vignette:

  • Statins do not work by altering HDL-to-LDL lipid transfer.
  • CETP inhibition (a different drug class, largely not a major USMLE focus clinically) would be expected to raise HDL prominently—not the hallmark “LDL drop + myalgias” statin picture.

Step takeaway: CETP is about lipoprotein exchange, not cholesterol synthesis rate-limiting control.

C. HMG-CoA synthase

What it does:
Catalyzes formation of HMG-CoA from acetoacetyl-CoA.

Two locations, two pathways (USMLE favorite):

  • Cytosolic HMG-CoA synthase → cholesterol synthesis pathway
  • Mitochondrial HMG-CoA synthase → ketogenesis (in liver mitochondria)

Why it’s wrong in this vignette:

  • Statins inhibit HMG-CoA reductase, not HMG-CoA synthase.
  • Blocking synthase would occur upstream and is not the mechanism of common LDL-lowering therapy.

Step takeaway:

  • Ketogenesis uses mitochondrial HMG-CoA synthase.
  • Cholesterol synthesis uses cytosolic HMG-CoA synthase, but the rate-limiting enzyme is still HMG-CoA reductase.

D. LCAT (Lecithin–cholesterol acyltransferase)

What it does:
Esterifies free cholesterol on HDL:

  • Converts cholesterol → cholesteryl ester (more hydrophobic) which moves into HDL core
  • Helps HDL mature (nascent discoid HDL → spherical HDL)

Why it’s wrong in this vignette:

  • LCAT is involved in reverse cholesterol transport, not hepatic cholesterol synthesis.
  • LCAT issues classically show up in genetic deficiency presentations (e.g., very low HDL, corneal opacities), not “statin started → myalgias + LDL drop.”

Step takeaway: LCAT = HDL maturation. Statins = lower hepatic cholesterol synthesis → ↑ LDL receptors.

E. LDL receptor (LDLR)

What it does:
Mediates endocytosis of LDL particles into hepatocytes and peripheral cells.

Why it’s wrong in this vignette:

  • Statins do not directly inhibit LDLR. They increase LDLR expression by lowering intracellular cholesterol.
  • LDLR is most commonly tested in familial hypercholesterolemia:
    • Autosomal dominant
    • Very high LDL, tendon xanthomas, early atherosclerosis
    • Defect in LDLR or ApoB-100 (ligand)

Step takeaway:

  • LDLR is the reason statins lower LDL so well (upregulation), but it’s not the direct drug target.

Rapid-Fire High-Yield: HMG-CoA Reductase & Statins

Regulation of HMG-CoA reductase (Step 1 gold)

  • Activated by: insulin (fed state)
  • Inhibited by: glucagon (fasting), cholesterol (feedback), statins
  • Dephosphorylated = active, phosphorylated = inactive (think: insulin promotes dephosphorylation)

What else uses cholesterol? (Step relevance)

Cholesterol is a precursor for:

  • Bile acids
  • Steroid hormones (cortisol, aldosterone, estrogen/testosterone, progesterone)
  • Vitamin D

Clinical tie-ins

  • Statins primarily reduce LDL
  • Mild TG reduction; slight HDL increase
  • Myopathy risk increases with:
    • Higher doses
    • Drug interactions (commonly tested): CYP inhibitors (e.g., macrolides, azoles, protease inhibitors)

Exam Strategy: How to Recognize “HMG-CoA Reductase” in One Pass

Look for:

  • High LDL + therapy that “inhibits rate-limiting step of cholesterol synthesis”
  • Myalgias ± ↑ CK after starting lipid therapy
  • Mechanism wording: “blocks conversion of HMG-CoA to mevalonate”

If the stem emphasizes HDL maturation → think LCAT.
If it emphasizes reverse cholesterol transport or HDL cholesterol acquisition → think ApoA-I / LCAT / SR-BI.
If it emphasizes endocytosis of LDL or tendon xanthomas → think LDLR / ApoB-100.

Key Takeaways (memorize-ready)

  • HMG-CoA reductase is the rate-limiting enzyme of cholesterol synthesis (HMG-CoA → mevalonate).
  • Statins inhibit HMG-CoA reductase → ↓ hepatic cholesterol → ↑ LDL receptors → ↓ LDL.
  • LCAT matures HDL; CETP swaps lipids between HDL and VLDL/LDL; LDLR clears LDL; HMG-CoA synthase is upstream and split by location (mito ketones vs cytosol cholesterol).
Back to all articles